Temple Faculty Physicians is experiencing technical issues with phone lines. If you are experiencing an emergency, please visit your nearest emergency room. If you would like to schedule an appointment with your provider or have general questions or requests, please contact us by using myTempleHealth.

myTempleHealth
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH
Back To Doctor Search

Hematology/Oncology

Sukhmani Kaur Padda, MD

Sukhmani Kaur Padda

Specialties

Hematology / Oncology

Loading ...
About Me
Offices
Publications
Ratings & Reviews
About Me
Offices

Office Locations

Temple University Hospital – Main Campus

3401 N. Broad Street

Philadelphia, PA 19140

800-TEMPLE-MED

Publications
Selected Publications

1. Waliany S, Zhu H, Wakelee H, Padda SK, Das M, Ramchandran K, Myall NJ, Chen T, Witteles RM, Neal JW. Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma. J Thorne Oncol. 2021 Aug 18:SI556-0864(21)02377-7. doi: 10.1016/j.jtho.2021.07.030. Online ahead of print. PMID: 34418561

2. Gencralova 0, Roy M, Hall E, Shah SA, Cunanan K, Fardccn T, Velazquez B, Chu G. Bruzzonc B, Cabot A, Fisher GA, Srinivas S, Fan AC, Haraldsdottir S, Wakelce HA, Neal JW, Padda SK, Johnson T, Heestand GM, Hsieh RW, Ramchandran K. Implementation ofa cloud-based electronic patient-reported outcome (cPRO) platform in patients with advanced cancer. J Patient Rep Outcomes. 2021 Sep 15;5(1):91. doi: 10.I I 86/s41687-021-00358-2. PMID: 34524558.

3. Das, M., Padcla, S.K., Weiss, J. Owonikoko, T. Advances in Treatment ofRecimcnt Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtabk Discussion. Adv 77,er, 2021 Sep 26:1-2 l. Doi: 10.1007/s12325-021-01909-1. Epub ahead of print PMID: 34564806; PMCID: PMC8475485.

4. Hellyer JA, White MN, Gardner RM, Cunanan K, Padda SK, Das M, Ramchandran K, Neal JW, Wakclcc HA. Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon l 9 Deletion Lung Cancer. Clin Lung Cancer. 2021 Oct 21:S1525-7304(21)00245-X. doi: 10.10I6/j.cllc.2021.09.004. Epub ahead of print. PMID: 34838441.

5. l'adda SK, Reckamp KL, Koczywas M, Neal JW, Kawashima J, Kong S, Huang DB, Kowalski M, Wakelce HA. A Phase lb Study of Erlotinib and Momelotinih for the Treatment of EGFR-Mutated, Tyrosine Kinase Inhibitor-Naive Metastatic Non-Small Cell Lung Cancer. Cancer Chemotherapy and Pharmacology, 2021 Nov 13. Doi: 10.1007/s00280-021-04369-0. Online ahead of print. PMID: 34773474.

6. White MN, Piper-Vallilo AJ, Gardner RM, Cunanan K, Neal JW, Das M, Padda SK, Ramchandran K, Chen TT, Sequist LV, Piotrowska Z, Wakelee HA. Chemotherapy plus immunotherapy or chemotherapy plus bcvacizumab versus chemotherapy alone in EGFR-mutant NSCLC after progression on osimertinib. Clinical Lung Cancer, 2021 Nov 11. Doi: JO.I 016/j.cllc.2021.11.001. Online ahead of print. PMID: 34887193.

7. Aredo JV, Wakelce HA, Neal JW, Padda SK. Afatinib After Progression on Osimcrtinib in EGFR­ Mutated Non-Small Cell Lung Cancer. Cancer Treatment and Research Communications. 2021 Dec 3;30:100497. doi: I0.1016/j.ctarc.2021.100497. Epub ahead of print. PMID: 34920242.

8. Daly ME, Singh N, Ismaila N, AnlonoffMB, Arenberg DA, Bradley J, David E, Dctterbeck F, Frlih M, Gubens MA, Moore AC, Padda SK, Patel JD, Phillips T, Qin A, Robinson C, Simone CB 2nd. Management of Stage Ill Non-Small-Cell Lung Cancer: ASCO Guideline. Journal of Clinical Oncology. 2021 Dec 22:JCO2 I 02528. doi: 10.1200/JC0.21.02528. Epub ahead of print. PMID: 34936470.

9. Thomas S, Raj R, Hwang G, PancirerD, HornbackerKM, CodimaA, Lui NS, Kunz P, Padda SK. Diffuse Idiopathic Pulmonary Ncuroendocrinc Cell Hyperplasia (DIPNECH): Clinical Characteristics and Progression to Carcinoid Tumor. European Respiratory Journal. 2022 Jan: 59 (I) 210I058; doi: 10.l183/13993003.01058-2021

10. Singha S, Hellyer J, Ouseph MM, Wakclec HA, Padda SK. Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors. JTO Clin Res Rep. 2022 Apr 21;3(5):100323. doi: 10.1016/j.jtocrr.2022.100323. PMID: 35601925; PMCID: PMC9121321.

Ratings & Reviews

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient Comments

Loading ...